CliffBio
small molecule

ZOLPIDEM TARTRATE

ZOLPIDEM TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOLPIDEM TARTRATE
Active ingredientZOLPIDEM TARTRATE
Strength6.25MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2013
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.